---

Postpartum Management of Women with GDM

---

1. Immediate Postpartum (Day 1-3)

Blood Glucose Management

Neonatal Care (from Govt of India guidelines)

• All babies born to GDM mothers are monitored for neonatal hypoglycemia (<45 mg/dL) within the first hour of birth and at 4-hour intervals until four stable readings ≥45 mg/dL are achieved.
• Watch for: respiratory distress, convulsions, hyperbilirubinemia.
• If hypoglycemic, refer to a higher centre with 10% dextrose IV infusion (100 mL/kg/day) under paediatric care.
• Children of GDM mothers should be marked as high-risk on the neonatal discharge card for surveillance of obesity, IGT, DM, hypertension, and metabolic syndrome.

---

2. Postpartum OGTT Screening

Timing

• Govt of India (NHM 2018): 75 g OGTT at 6 weeks postpartum. (ANM performs this at the community level.)
• FOGSI (2024): Postpartum screening at 6-12 weeks for all women with GDM.
• RSSDI (2022): Reassessment at 6-12 weeks postpartum with 75 g OGTT.

Interpretation of 75 g 2-hour OGTT (non-pregnant criteria)

Subsequent Long-term Screening

• Govt of India: If OGTT is normal at 6 weeks, repeat at 6 months, then every year.
• FOGSI: All women with normal OGTT advised to repeat testing every year.
• RSSDI: Annual screening for prediabetes/T2DM; intensive lifestyle intervention (and/or metformin) for those with prediabetes.

---

3. Breastfeeding

• FOGSI (2024): Breastfeeding is strongly recommended for all women with DM, whether pregestational or gestational.
• RSSDI (2022): Breastfeeding is recommended as it reduces maternal T2DM risk by ~32%.
• Govt of India / RSSDI: Breastfeeding supports weight management and lowers future NCD risk for both mother and child.

---

4. Lifestyle Modification and Weight Management

• FOGSI (2024) and Govt of India: Women with GDM are advised to continue a healthy diet and regular exercise to reduce the risk of T2DM.
• Weight retention postpartum is a significant risk factor for future cardiometabolic complications - active weight loss is encouraged.
• RSSDI (2022): Minimum 150 min/week of moderate-intensity physical activity; ≥30 min of aerobic exercise daily (walking, cycling, swimming).
• Medical nutrition therapy (MNT) principles continue into the postpartum period.

---

5. Contraception and Interconceptional Care

• FOGSI (2024): In women without vascular complications, any contraceptive method may be prescribed (MEC Category 1 or 2). A contraceptive plan should be discussed and implemented before discharge.
• Govt of India (2018): Counseling on postpartum family planning is part of the discharge plan.
• RSSDI (2022): Reminder about the importance of contraception, pre-conception care, and planning for future pregnancies.
• Euglycemic and prediabetic women are given regular follow-up and contraceptive advice.

---

6. Discharge Counseling (FOGSI 2024)

1. Continuation of healthy diet and exercise
2. Breastfeeding - strongly encouraged
3. Contraception - method to be chosen and initiated
4. Need for follow-up OGTT at 6-12 weeks postpartum
5. Risk of T2DM - significantly higher risk of progression within 5-10 years
6. Other NCDs - dyslipidemia, hypertension, cardiovascular disease
7. Child's risk - offspring are high-risk for childhood obesity, metabolic syndrome, IGT, T2DM, and CVD in later life

---

7. Long-term Surveillance and NCD Linkage

• Govt of India (2018): GDM is classified as part of the NCD programme. Long-term follow-up at NCD clinics, postpartum care clinics, and paediatric setups as per programmatic protocols.
• FOGSI (2024): All women with GDM are advised to visit the clinic for preconceptional evaluation before any subsequent pregnancy.
• RSSDI (2022): Preconception care should be introduced in all women with history of GDM before planning the next pregnancy.
• Postpartum psychosocial assessment and support for self-care is recommended (Govt of India 2018 / RSSDI 2022).

---

Risk Reminder (FOGSI 2024)

• 30% risk of abnormal OGTT postpartum
• Two-thirds risk of recurrence of GDM in the next pregnancy
• 10-fold increased risk of T2DM compared to non-GDM women
• Increased risk of dyslipidemia, hypertension, and cardiovascular disease

---

• FOGSI Hyperglycemia in Pregnancy (2024)
• Govt of India MoHFW National Guidelines for GDM (2018) - NHM
• RSSDI Clinical Practice Recommendations 2022

---

Postpartum Insulin Management: GDM on High-Dose Insulin vs. Pre-existing T2DM

---

The Physiological Basis

---

CATEGORY 1: Women with GDM on Insulin Antenatally (including high-dose)

Immediate Postpartum (Day 0-3)

What if Blood Glucose Remains High After Delivery?

• If postpartum blood glucose is ≥140 mg/dL, the woman should be re-evaluated for pre-existing undetected T2DM or early diabetes.
• Metformin can be continued (or started) if postpartum blood glucose is high - it is safe during breastfeeding. (DIPSI 2021)
• Insulin is restarted only if glucose remains uncontrolled on lifestyle measures + metformin.

Was the Woman on Very High Antenatal Insulin Doses?

• Are at the highest risk of persistent hyperglycemia postpartum
• Should be fast-tracked for postpartum 75 g OGTT at 6 weeks
• If overt diabetes confirmed (2-hr ≥200 mg/dL or FPG ≥126 mg/dL) - refer to diabetic clinic for long-term therapy
• Should not be treated as routine GDM postpartum

---

CATEGORY 2: Women with Pre-existing Type 2 Diabetes (Pre-gestational T2DM)

Insulin Dose Reduction Protocol

• Third-trimester insulin doses can be 0.9-1.2 units/kg/day due to maximal placental insulin resistance
• Postpartum requirements may be even lower than pre-pregnancy levels initially
• Women who were on NPH or premixed insulin: dose should be individualized and reduced

Resuming Oral Hypoglycemic Agents (OHAs) - Pre-gestational T2DM

FOGSI 2024 Key Statement: "Pregestational diabetic women previously on oral hypoglycemics should resume the same therapy; women who were on insulin need reduced insulin dose titrated with blood glucose levels."

Blood Glucose Monitoring Frequency (T2DM Postpartum)

• SMBG at minimum: fasting + 2-hr post breakfast + 2-hr post-lunch + 2-hr post-dinner
• This is particularly relevant for the first 1-2 weeks postpartum when dose titration is happening
• Women on insulin while breastfeeding: eat a snack before or during breastfeeding to prevent hypoglycemia (RSSDI 2022)

---

CATEGORY 3: Special Situation - Breastfeeding and Insulin

• Breastfeeding itself lowers blood glucose due to glucose utilization for milk production
• Risk of hypoglycemia is highest during and immediately after feeds
• RSSDI recommendation: Advise women with insulin-treated diabetes that they are at increased risk of hypoglycemia in the postnatal period, especially when breastfeeding
• Advise them to have a meal or snack available before or during feeds
• Insulin dose may need further reduction once breastfeeding is fully established
• An individualized diabetes diet for breastfeeding mothers is recommended (RSSDI Insulin Consensus 2019)

---

Postpartum OGTT - Mandatory for Both Groups

---

Summary Algorithm

DELIVERY
    |
    ├── GDM on insulin
    │     ├── STOP insulin at delivery
    │     ├── Check BG on Day 3
    │     ├── If BG normal → lifestyle counseling, OGTT at 6 weeks
    │     └── If BG ≥140 mg/dL → consider metformin, re-evaluate for T2DM
    │
    └── Pre-existing T2DM on insulin
          ├── REDUCE insulin by ≥50% immediately at delivery
          ├── SMBG every 2-4 hours initially
          ├── Resume metformin immediately (safe in breastfeeding)
          ├── Avoid SGLT2i, GLP-1, DPP-4i in breastfeeding
          ├── Titrate insulin downward over days-weeks
          ├── Extra snack before/during breastfeeding feeds
          └── Set non-pregnant glycemic targets; long-term T2DM follow-up

---

• FOGSI Hyperglycemia in Pregnancy (2024)
• DIPSI/ICOG GDM Guidelines 2021
• Govt of India NHM National GDM Guidelines
• RSSDI Clinical Practice Recommendations 2022
• RSSDI Insulin Therapy Consensus 2019

---

Evaluation of Infertility

---

Definition

• Women ≥32 years: expedited evaluation after 6 months of failed attempts
• Women <32 years with risk factors (family history of early menopause, known PCOS, prior pelvic surgery, etc.): also evaluated after 6 months or earlier
• ~30% of couples will remain unexplained infertility even after complete workup

---

Principle: Couple-Oriented, Concurrent Evaluation

1. Semen abnormalities (male factor)
2. Ovulatory dysfunction
3. Tubal/peritoneal factor
4. Uterine/cervical factor
5. Unexplained (~30%)

---

PART A: FEMALE EVALUATION

1. History

2. Physical Examination

3. Investigations - Female

A. Ovulation Assessment

B. Ovarian Reserve Testing

AMH is the most useful marker: predicts hyper- vs. hypo-response to stimulation; especially valuable when AFC is low or woman is >35 years. (Tietz Textbook, 7th Ed)

C. Endocrine Profile

Draw prolactin fasting, early in the day - levels elevate after meals and stress.

D. Tubal and Uterine Evaluation

---

PART B: MALE EVALUATION

1. History

• Duration of infertility; prior pregnancies with same/different partner
• Reproductive history: undescended testis (cryptorchidism), orchitis, testicular trauma, torsion
• Sexual history: erectile dysfunction, ejaculatory dysfunction, STIs
• Surgical history: hernia repair (vas deferens injury), pelvic/retroperitoneal surgery, varicocelectomy, vasectomy reversal
• Medical history: chemotherapy, radiotherapy, chronic illness, diabetes
• Medications: anabolic steroids (suppress spermatogenesis), sulfasalazine, nitrofurantoin
• Family history: genetic conditions, cystic fibrosis (CBAVD)
• Lifestyle: smoking, alcohol, heat exposure (hot baths, laptop on lap), occupational gonadotoxins

2. Physical Examination

3. Semen Analysis (Cornerstone of Male Evaluation)

4. Further Male Investigations

---

Diagnostic Algorithm for Female Infertility

---

PART C: WHEN TO EXPEDITE (Indian Context - FOGSI)

• Woman ≥32 years (faster ovarian aging in Indian women)
• Family history of early menopause
• Known/suspected PCOS, endometriosis, uterine anomalies
• Prior pelvic surgery, chemotherapy/radiation
• Oligomenorrhea or amenorrhea (anovulatory - no need to wait 12 months)
• Known male factor (azoospermia, prior vasectomy)
• Both partners HIV positive (immediate referral)

---

PART D: BASIC INFERTILITY WORKUP - SUMMARY TABLE

---

• Tietz Textbook of Laboratory Medicine, 7th Ed - Initial Evaluation of Female Infertility, p. 2381-2385
• Smith & Tanagho's General Urology, 19th Ed - Evaluation of Male Infertility, p. 745
• FOGSI Best Practice Recommendations for Infertility Management - PMC10942128
• WHO/NCBI Approach to Evaluation of Infertility